Can-Fite BioPharma (NYSE:CANF) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a report issued on Monday. The firm set a “sell” rating on the stock.

CANF has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and set a $10.00 target price on shares of Can-Fite BioPharma in a report on Tuesday, December 31st.

Can-Fite BioPharma Trading Down 3.0 %

CANF stock opened at $1.50 on Monday. Can-Fite BioPharma has a 12-month low of $1.29 and a 12-month high of $4.69. The stock has a market cap of $5.32 million, a price-to-earnings ratio of -0.84 and a beta of 1.36. The business’s 50-day moving average is $1.64 and its 200 day moving average is $2.16.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers boosted its holdings in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,880 shares of the company’s stock after acquiring an additional 9,935 shares during the period. Rhumbline Advisers owned 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent reporting period. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.